1.34
price down icon0.74%   -0.02
after-market アフターアワーズ: 1.35 0.01 +0.75%
loading
前日終値:
$1.36
開ける:
$1.36
24時間の取引高:
34,977
Relative Volume:
0.12
時価総額:
$5.37M
収益:
-
当期純損益:
$-6.78M
株価収益率:
-0.375
EPS:
-3.5729
ネットキャッシュフロー:
$-4.67M
1週間 パフォーマンス:
-8.16%
1か月 パフォーマンス:
-12.34%
6か月 パフォーマンス:
+12.50%
1年 パフォーマンス:
+1,018%
1日の値動き範囲:
Value
$1.30
$1.37
1週間の範囲:
Value
$1.29
$1.53
52週間の値動き範囲:
Value
$0.10
$6.80

Clearmind Medicine Inc Stock (CMND) Company Profile

Name
名前
Clearmind Medicine Inc
Name
セクター
Healthcare (1196)
Name
電話
-
Name
住所
-
Name
職員
4
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
CMND's Discussions on Twitter

CMND を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
CMND 1.34 5.37M 0 -6.78M -4.67M -3.5729
VRTX 450.37 115.10B 10.63B -479.80M -1.35B 13.33
REGN 744.50 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 596.74 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.80 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 108.23 24.89B 3.30B -501.07M 1.03B 11.54

Clearmind Medicine Inc (CMND) 最新ニュース

pulisher
Nov 04, 2024

SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com

Nov 04, 2024
pulisher
Oct 22, 2024

Clearmind Medicine (NASDAQ:CMND) Shares Down 12.3% – What’s Next? - Defense World

Oct 22, 2024
pulisher
Oct 11, 2024

Clearmind Medicine Inc [CMND] Revenue clocked in at $0.00 million, down -51.60% YTD: What’s Next? - The DBT News

Oct 11, 2024
pulisher
Oct 11, 2024

Clearmind advances trial for alcohol use disorder therapy - Investing.com

Oct 11, 2024
pulisher
Oct 11, 2024

Clearmind advances trial for alcohol use disorder therapy By Investing.com - Investing.com Australia

Oct 11, 2024
pulisher
Oct 10, 2024

Clearmind Medicine Inc (NASDAQ: CMND): Is Its Value Too High Compared To Others? - Stocks Register

Oct 10, 2024
pulisher
Oct 10, 2024

Clearmind Medicine Inc Inc. (CMND) Price Performance: A Technical Analysis Perspective - The InvestChronicle

Oct 10, 2024
pulisher
Oct 10, 2024

Examining CMND’s book value per share for the latest quarter - US Post News

Oct 10, 2024
pulisher
Oct 10, 2024

Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site - Marketscreener.com

Oct 10, 2024
pulisher
Oct 09, 2024

Rail Vision secures $20 million equity deal with Yorkville - Investing.com

Oct 09, 2024
pulisher
Oct 08, 2024

SciSparc gains as Clearmind partnership yields 3 new international patent applications - MSN

Oct 08, 2024
pulisher
Oct 01, 2024

Clearmind Medicine Completed Type A Meeting with the FDA - GlobeNewswire

Oct 01, 2024
pulisher
Sep 30, 2024

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment - Marketscreener.com

Sep 30, 2024
pulisher
Sep 26, 2024

Clearmind Medicine appoints new board member - Investing.com

Sep 26, 2024
pulisher
Sep 24, 2024

Clearmind, SciSparc slide amid weight-loss study results - MSN

Sep 24, 2024
pulisher
Sep 19, 2024

Could Psychedelics End Binge Drinking? A Breakthrough Patent Says Yes - MSN

Sep 19, 2024
pulisher
Sep 17, 2024

Clearmind Medicine patents new addiction treatment - Investing.com India

Sep 17, 2024
pulisher
Sep 16, 2024

SciSparc Unveils Breakthrough Ibogaine Therapy Patent - TipRanks

Sep 16, 2024
pulisher
Sep 16, 2024

Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering - The Bakersfield Californian

Sep 16, 2024
pulisher
Sep 16, 2024

SciSparc-Clearmind Medicine Collaboration Announces the - GlobeNewswire

Sep 16, 2024
pulisher
Sep 16, 2024

SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy - StockTitan

Sep 16, 2024
pulisher
Sep 14, 2024

Contrasting Clearmind Medicine (NASDAQ:CMND) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World

Sep 14, 2024
pulisher
Sep 13, 2024

Clearmind Medicine files patent for PTSD treatment compounds - Investing.com

Sep 13, 2024
pulisher
Sep 12, 2024

Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment - Morningstar

Sep 12, 2024
pulisher
Sep 11, 2024

SciSparc shares up on patents filed for psychedelic compounds with Clearmind - MSN

Sep 11, 2024
pulisher
Sep 07, 2024

SciSparc and Clearmind Innovate Mental Health Treatment - TipRanks

Sep 07, 2024
pulisher
Sep 06, 2024

Clearmind Medicine files patent for novel MDMA therapy - Investing.com

Sep 06, 2024
pulisher
Sep 06, 2024

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - Yahoo Finance UK

Sep 06, 2024
pulisher
Sep 06, 2024

SciSparc-Clearmind Medicine Collaboration Leads to - GlobeNewswire

Sep 06, 2024
pulisher
Sep 06, 2024

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent ... - The Bakersfield Californian

Sep 06, 2024
pulisher
Sep 02, 2024

A History of Outperforming Analyst Forecasts and Beating the Odds: Clearmind Medicine Inc (CMND) - SETE News

Sep 02, 2024
pulisher
Sep 02, 2024

Financial Metrics Check: Clearmind Medicine Inc (CMND)’s Ratios for Trailing Twelve Months - The Dwinnex

Sep 02, 2024
pulisher
Aug 29, 2024

Clearmind and SciSparc file patent for ketamine-based therapy - Investing.com

Aug 29, 2024
pulisher
Aug 29, 2024

SciSparc and Clearmind Innovate in Mental Health Therapy - TipRanks

Aug 29, 2024
pulisher
Aug 29, 2024

Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment - Morningstar

Aug 29, 2024
pulisher
Aug 29, 2024

SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination - Yahoo Finance

Aug 29, 2024
pulisher
Aug 26, 2024

Clearmind Biomedical Announces FDA Clearance and First U.S. Surgery of the Neuroblade System for Minimally Invasive Neurosurgery - PR Newswire

Aug 26, 2024
pulisher
Aug 25, 2024

Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Market Exclusive

Aug 25, 2024
pulisher
Aug 23, 2024

CMND’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle

Aug 23, 2024
pulisher
Aug 22, 2024

Clearmind receives patent for drug to treat binge behavior - Green Market Report

Aug 22, 2024
pulisher
Aug 22, 2024

Clearmind Medicine Inc (CMND) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle

Aug 22, 2024
pulisher
Aug 21, 2024

Clearmind Medicine secures new US patent for binge behavior regulator - Investing.com India

Aug 21, 2024
pulisher
Aug 21, 2024

Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment - Yahoo Finance

Aug 21, 2024
pulisher
Aug 20, 2024

Clearmind Medicine Inc (CMND) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News

Aug 20, 2024
pulisher
Aug 19, 2024

Is CMND’s price to cash per share ratio a concern for investors? - US Post News

Aug 19, 2024
pulisher
Aug 19, 2024

Financial Metrics Unveiled: Clearmind Medicine Inc (CMND)’s Key Ratios in the Spotlight - The Dwinnex

Aug 19, 2024
pulisher
Aug 16, 2024

Thinking about buying stock in Brainstorm Cell Therapeutics, Cle - GuruFocus.com

Aug 16, 2024
pulisher
Aug 16, 2024

Clearmind, Yissum Apply for International Patent for Psychedelics - MarketWatch

Aug 16, 2024
pulisher
Aug 16, 2024

Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders - StockTitan

Aug 16, 2024
pulisher
Aug 10, 2024

Clearmind Medicine (NASDAQ:CMND) Stock Price Down 0.8% - Defense World

Aug 10, 2024
pulisher
Aug 09, 2024

Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket - Benzinga

Aug 09, 2024

Clearmind Medicine Inc (CMND) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.56%
$367.36
price up icon 0.77%
$194.56
price up icon 0.07%
$108.23
price up icon 5.98%
大文字化:     |  ボリューム (24 時間):